The American Academy Of Pain Medicine

The physicians' voice in pain medicine
  • Foundation
  • Store
  • Career Center
  • Press
  • Join-Renew
Search: Go
Member Login: Login

Enter the AAPM
Members' Community

  • Member Center
  • Patient Center
  • Library
  • Advocacy
  • Practice Management
  • CME
  • Annual Meeting
  • Safe Prescribing Resources
  • PI-CME Portal

Library

Home > Library > For Pain Researchers > 2013 Poster Abstracts
  • Research in the News
  • For Pain Researchers
    • 2013 Poster Abstracts
    • 2012 Poster Abstracts
    • Research Resources
    • Research Presentations
    • Search Clinical Trials (NIH)
    • Register a Clinical Trial (NIH)
    • Medline - US National Library of Medicine
  • Clinical Guidelines and Resources
  • Pain Facts
  • Archives
  • FDA Updates, Recalls and Warnings
  • Presented at the 2013 AAPM Annual Meeting « Back

    175

    Tx360™: A Non-invasive Technique for Sphenopalatine Ganglion Nerve Block in the Treatment of Trigeminal Neuralgia

    Kenneth D. Candido, MD, kdcandido@yahoo.com1, Ruben Sauer, MD2, Lalida Chupatanakul, MD3, Nebojsa Nick Knezevic, MD PhD4, (1) Advocate Illinois Masonic Medical Center, Chicago, Illinois, (2) Chicago Anesthesia Pain Specialist, Chicago, Illinois, (3) Chicago Anesthesia Pain Specialist Research Department, Chicago, Illinois, (4) University of Illinois, Chicago, Illinois

    Introduction: The sphenopalatine ganglion, located in the posterior part of the middle nasal turbinate, is involved in pain associated indirectly with trigeminal neuralgia (TN). Treatment can be done by using non-surgical (cotton-tip-applicator), and surgical procedures which could cause nerve damage and sensory loss. The purpose of this case series is to present a novel non-invasive treatment for sphenopalatine ganglion nerve block (SPGB). Material and Methods: After IRB approval, patients were evaluated for pain using a numeric rating scale (NRS), quality of life questionnaire, Patient Global Impression of Change (PGIC), and patient satisfaction. The Tx360™ Nasal Applicator with 1ml 0.5% Marcaine/1:200,000 epinephrine were used to perform SPGB. Pre-procedural evaluations were repeated 15 minutes, 30 minutes, and every week up to day 28 day post-procedure. Results: Three female patients, ages 15, 18 and 43 presented with TN. The average baseline NRS were 7, with improvement during the first 15 minutes an average of 2 on the NRS, which persist on the first day post-procedure. At the end of the 28 days the average daily increased pain was up to 4 on NRS. All three patients were completely satisfied, and the PGIC status was very much improved on average. One patient developed minimal bleeding from the nose on the first day which stopped spontaneously. Conclusions: SPGB with Tx360™ provided clinically significant pain relief with minimal complications. Pain increase during the 28 days follow-up may indicate the need for repeating the procedure. Long term studies are needed to assess the efficacy of this technique.

    Funding: None

  • Home
  • Member Center
  • Patient Center
  • Library
  • Advocacy
  • Practice Management
  • CME
  • Annual Meeting
  • Contact Us
  • Members' Community
  • Privacy Policy
  • Sitemap
Close

Members Only Alert Message

Please login to access AAPM member only information.
Forgot your login information?

Sign Up Today!

Join AAPM today and be part of the primary organization for physicians practicing in the specialty of pain medicine and begin accessing AAPM member benefits. 

Join
Or

Log In

Please log in and you will be redirected to the requested page.

Log In